Profound Medical (TSE:PRN) Hits New 12-Month Low – What’s Next?

Profound Medical Corp. (TSE:PRN)’s stock price hit a new 52-week low during trading on Monday . The company traded as low as C$8.66 and last traded at C$9.34, with a volume of 1674 shares. The stock had previously closed at C$9.28.

Wall Street Analyst Weigh In

Separately, Raymond James raised shares of Profound Medical to a “strong-buy” rating in a report on Saturday, November 9th.

Profound Medical Stock Down 4.7 %

The company has a debt-to-equity ratio of 16.95, a quick ratio of 14.98 and a current ratio of 8.61. The stock’s 50 day moving average price is C$10.56 and its 200-day moving average price is C$11.32. The company has a market cap of C$216.40 million, a PE ratio of -5.33 and a beta of 0.81.

Profound Medical (TSE:PRN) last posted its quarterly earnings results on Thursday, November 7th. The company reported C($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.42) by C($0.10). During the same quarter last year, the firm posted ($0.35) EPS. On average, analysts predict that Profound Medical Corp. will post -1.9000001 earnings per share for the current year.

Insider Buying and Selling

In other Profound Medical news, Director Arun Menawat Dr. acquired 20,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average cost of C$10.65 per share, for a total transaction of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino bought 13,333 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The shares were acquired at an average price of C$10.65 per share, with a total value of C$141,996.45. 8.62% of the stock is owned by corporate insiders.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.